Clinical Trials
10 trialsNCT05768139 2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2 Recruiting
NCT06993844 2026-05-06
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Phase 1/2 Recruiting
NCT07558733 2026-04-30
Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer
Faeth Therapeutics
Phase 1/2 Recruiting
NCT05683418 2026-04-22
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Totus Medicines
Phase 1 Recruiting
NCT03678883 2026-04-03
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Phase 2 Active not recruiting
NCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT04480814 2025-12-30
Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood & Primary Tumor in ER+/HER2- MBC
Pharmassist Ltd
Completed
NCT02000089 2025-10-09
CAPS5
Johns Hopkins University
Phase 3 Recruiting
NCT04520269 2025-09-25
A Single Arm, Phase Ib/II Trial of Single Agent Pacritinib in Patients With 1q21.3 Amplified Solid Tumors Enriching for Interleukin-1 Receptor-associated Kinase 1 Pathway Activation (PAIR)
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT01226316 2025-06-29
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
AstraZeneca
Phase 1 Completed